The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Homeopathy in Patients Suffering From Long COVID-19 (LONGCOVIHOM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06002230
Recruitment Status : Completed
First Posted : August 21, 2023
Last Update Posted : August 22, 2023
Sponsor:
Collaborator:
Sigmund Freud PrivatUniversitat
Information provided by (Responsible Party):
Michael Frass, Medical University of Vienna

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
In some patients, coronavirus (COVID-19) can cause symptoms that last weeks or even months after the infection has gone. The aim of this study was to describe the effect of adjunctive individualized homeopathic treatment delivered to Long-COVID-19 patients with previously confirmed symptomatic SARS-CoV-2 infection.

Condition or disease Intervention/treatment
Adjustment Reaction With Physical Symptoms Drug: Homeopathic medicines

Detailed Description:

All patients had been tested positive for SARS-CoV-2 before having developed Long-COVID-19 symptoms. Several testing methods were carried out in each patient to analyze a SARS-CoV-2 infection. For a confirmed infection, at least 3 out of these 5 tests had to be positive. Tests for the orthomyxoviruses influenza A and B, human metapneumovirus (hMPV) and paramyxoviruses were negative unless stated otherwise.

The homeopathic physician treated all Long-COVID-19 patients by individualized homeopathy. Repertorization of the symptoms of the current pandemic and a search in the current homeopathic literature on COVID-19 was performed using computer program. All available homeopathic medicinal products (HMPs) could be chosen by the treating physician.

Modified MONARCH criteria were assessed post hoc by all authors. Deviations were solved by discussion in person. Clinical outcome of case reports was evaluated using the "Modified Naranjo Criteria for Homeopathy-Causal Attribution Inventory". Eight points is assumed as the limit for potential correlation between homeopathic therapy and amelioration of the symptoms or healing in chronic cases.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Use of Homeopathy in Patients Suffering From Long COVID-19 (LONGCOVIHOM): A Retrospective Case Series
Actual Study Start Date : January 5, 2021
Actual Primary Completion Date : October 19, 2021
Actual Study Completion Date : August 10, 2023

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patients treated with individualized homeopathy
Patients suffering from symptoms of Long COVID-19 were treated with individualized homeopathy.
 Drug: Homeopathic medicines
Globules were administered orally..
Other Name: Homeopathic medicinal products


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Modified Naranjo criteria [ Time Frame: 3 days ]
    10 Naranjo criteria are evaluated, eight points is assumed as the limit for potential correlation between homeopathic therapy and amelioration of the symptoms or healing in chronic cases.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Sampling Method:   Non-Probability Sample
Study Population
Patients suffering from Long COVID-19 symptoms following recovery from SARS-CoV-2 infection.
Criteria

Inclusion Criteria:

Long COVID-19 symptoms following recovery from SARS-CoV-2 infection

Exclusion Criteria:

Patients not signing informed consent

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06002230


Locations
Layout table for location information
Austria
Sigmund Freud Private University
Vienna, Austria, 1020
Sponsors and Collaborators
Michael Frass
Sigmund Freud PrivatUniversitat
Investigators
Layout table for investigator information
Study Director: Michael Frass, MD Institute for Homeopathic Research
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Michael Frass, Clinical professor, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT06002230    
Other Study ID Numbers: 111
First Posted: August 21, 2023    Key Record Dates
Last Update Posted: August 22, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Michael Frass, Medical University of Vienna:
Complementary therapy
Homeopathy
COVID-19
Long-COVID-19
SARS-CoV-2
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Post-Acute COVID-19 Syndrome
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
 Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Post-Infectious Disorders
Chronic Disease
Disease Attributes
Pathologic Processes